Elmar Kraus
Stock Analyst
(n/a)
# 4,652
Out of 4,654 analysts
12
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Elmar Kraus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly | Downgrades: Hold | $820 | $746.20 | +9.89% | 4 | Feb 21, 2024 | |
| GSK GSK | Downgrades: Hold | n/a | $33.35 | - | 1 | Feb 11, 2022 | |
| AZN AstraZeneca | Upgrades: Hold | n/a | $63.23 | - | 1 | Feb 11, 2022 | |
| PFE Pfizer | Upgrades: Buy | $41 | $24.80 | +65.32% | 2 | Feb 4, 2021 | |
| MDT Medtronic | Downgrades: Hold | $92 | $87.53 | +5.11% | 2 | May 14, 2020 | |
| GILD Gilead Sciences | Upgrades: Buy | n/a | $88.40 | - | 2 | Mar 18, 2020 |
Eli Lilly
Feb 21, 2024
Downgrades: Hold
Price Target: $820
Current: $746.20
Upside: +9.89%
GSK
Feb 11, 2022
Downgrades: Hold
Price Target: n/a
Current: $33.35
Upside: -
AstraZeneca
Feb 11, 2022
Upgrades: Hold
Price Target: n/a
Current: $63.23
Upside: -
Pfizer
Feb 4, 2021
Upgrades: Buy
Price Target: $41
Current: $24.80
Upside: +65.32%
Medtronic
May 14, 2020
Downgrades: Hold
Price Target: $92
Current: $87.53
Upside: +5.11%
Gilead Sciences
Mar 18, 2020
Upgrades: Buy
Price Target: n/a
Current: $88.40
Upside: -